Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

10.75USD
18 Sep 2017
Change (% chg)

-- (--)
Prev Close
$10.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,797
52-wk High
$14.60
52-wk Low
$5.50

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.16
Market Cap(Mil.): $271.76
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 79.97 16.21
EPS (TTM): -- -- --
ROI: -- 3.01 14.56
ROE: -- 4.79 13.83

BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln

* Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​ Source text: (http://bit.ly/2wFKm1k) Further company coverage:

Aug 08 2017

BRIEF-Stemline Therapeutics Q2 loss per share $0.66

* Stemline Therapeutics reports second quarter 2017 financial results

Aug 08 2017

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

Jun 23 2017

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

May 10 2017

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

Mar 23 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,466 +23.50
Eisai Co., Ltd (4523.T) ¥5,869 +68.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,479 +9.00
Pfizer Inc. (PFE.N) $35.55 +0.19
Novartis AG (NOVN.S) CHF82.35 +0.25
Merck & Co., Inc. (MRK.N) $65.99 -0.17
Roche Holding Ltd. (ROG.S) CHF244.80 +1.10
Roche Holding Ltd. (RO.S) CHF245.30 +1.30
Sanofi SA (SASY.PA) €82.11 +0.59
GlaxoSmithKline plc (GSK.L) 1,453.50 -3.50

Earnings vs. Estimates